menu
    • menu
    [{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase III","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Ferring Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","graph1":"Gastroenterology","graph2":"Approved","graph3":"Ferring Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ferring Pharmaceuticals \/ UCB","highestDevelopmentStatusID":"12","companyTruncated":"Ferring Pharmaceuticals \/ UCB"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Highmark","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","graph1":"Gastroenterology","graph2":"Approved","graph3":"Highmark","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highmark \/ UCB","highestDevelopmentStatusID":"12","companyTruncated":"Highmark \/ UCB"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Certolizumab Pegol","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"},{"orgOrder":0,"company":"Xbrane Biopharma","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","graph1":"Immunology","graph2":"Preclinical","graph3":"Xbrane Biopharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Xbrane Biopharma \/ Biogen Inc.","highestDevelopmentStatusID":"4","companyTruncated":"Xbrane Biopharma \/ Biogen Inc."},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Certolizumab Pegol","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"UCB Pharma S.A \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"UCB Pharma S.A \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Certolizumab Pegol

    Menu

    Certolizumab Pegol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            UCB Pharma S.A

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            UCB Reinforces Commitment to Rheumatology with 15 Abstracts Including New Late-Breaking Data at ACR Convergenc...

                            Details : CIMZIA (certolizumab pegol) is the only Fc-free, PEGylated anti-TNF (Tumor Necrosis Factor). CIMZIA has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha.

                            Brand Name : Cimzia

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 08, 2022

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xbrane Biopharma

                            Sweden arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Xbrane Biopharma

                            Sweden arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Biogen

                            Deal Size : $88.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIAÂ...

                            Details : Under the terms of the agreement, Biogen will gain exclusive global regulatory, manufacturing, and commercial rights to Xcimzaneâ„¢ and will be the Marketing Authorization Holder.

                            Brand Name : Xcimzane

                            Molecule Type : Large molecule

                            Upfront Cash : $8.0 million

                            February 07, 2022

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Biogen

                            Deal Size : $88.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            UCB Pharma S.A

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Data from UCB's Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Wom...

                            Details : The findings confirm that patients with axSpA who achieve sustained remission benefit from continued certolizumab pegol treatment, either with the full or reduced maintenance dose - over treatment withdrawal.

                            Brand Name : Cimzia

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 01, 2021

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Highmark

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Highmark

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : UCB Pharma S.A

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Highmark Forges Outcomes-Based Contract with UCB for Anti-Inflammatory Drug CIMZIA® (certolizumab pegol)

                            Details : The outcomes-based agreement for the CIMZIA lyophilized powder healthcare professional administered formulation applies to all commercial members in Highmark's national and core health insurance markets in Pennsylvania, West Virginia, and Delaware.

                            Brand Name : Cimzia

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 18, 2020

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : UCB Pharma S.A

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            UCB Pharma S.A

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            UCB'S CIMZIA is the First and Only Biologic Approved in Europe with the Option for a Reduced Maintenance Dose ...

                            Details : EMA has approved a label extension for CIMZIA for use in adult patients with axial spondyloarthritis (axSpA) at a reduced maintenance dose of 200 mg every four weeks, once sustained remission is achieved after one year of CIMZIA 200 mg every two weeks o...

                            Brand Name : Cimzia

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 05, 2020

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Ferring Pharmaceuticals

                            Switzerland arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : UCB Pharma S.A

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            UCB and Ferring Pharmaceuticals Announce Co-Promotion of CIMZIA® for the Treatment of Moderate to Severe Croh...

                            Details : Ferring joins with UCB to promote CIMZIA prefilled syringe for Crohn’s disease in the United States. Co-promotion strengthens commitment to patients living with Crohn’s disease by reaching more gastroenterologists while also continuing patient suppor...

                            Brand Name : Cimzia

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 08, 2020

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : UCB Pharma S.A

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            UCB Pharma S.A

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            UCB Pharma S.A

                            Belgium arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            UCB Shares Breadth of Innovative New Data from Rheumatology Portfolio for EULAR 2020 E-Congress

                            Details : Four-year results from the RAPID-axSpA study of CIMZIA[®] (certolizumab pegol) highlight the importance of early, effective and long-term treatment targeting inflammation.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 04, 2020

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth